Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Vladimir Hugec (NPI 1790723328)

Field	Value
Entity Type	Individual
Organization	Vladimir Hugec
Address	1580 Beam Ave
City	Maplewood
State	MN
ZIP	55109
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 4, 2006

Payer Source	Total Paid
Medicare	$1.8M
Medicaid	$0

Key Findings

This provider’s Medicare activity is concentrated in oncology immunotherapy and diagnostic imaging: the top three revenue codes are J9271 ($481.6K, 29.0%), J9299 ($292.8K, 17.6%), and A9595 ($143.5K, 8.6%), and those top 3 codes account for 55.2% of this provider's total Medicare revenue. The presence of high-revenue, drug-administration codes (pembrolizumab and nivolumab) alongside a PET diagnostic code suggests an office-based oncology practice that delivers immunotherapy infusions and coordinates advanced imaging for staging or response assessment.

Revenue concentration is high within Medicare: total Medicare revenue is $1.8M and more than half of that is captured by the three leading codes (55.2%). This concentration indicates a business model heavily dependent on a small set of high-cost oncology drugs and associated diagnostics rather than a broad, diversified billing mix.

Payer mix is effectively single-payer at the claims level: the record shows Total Medicare revenue of $1.8M and no Medicaid billing on file, so the practice operates with Medicare as the dominant public payer and has no measurable Medicaid footprint. That single-payer profile may reflect the provider’s patient panel, referral patterns, or contractual/credentialing choices rather than a balanced Medicare–Medicaid mix.

On national competitive standing for the top oncology drugs, this provider is a modest participant: J9271 (pembrolizumab) “ranks #1028 of 1841 providers nationally (43th percentile; typical, unremarkable volume for this code)” and J9299 (nivolumab) “ranks #302 of 505 providers nationally (40th percentile; typical, unremarkable volume for this code)”. A9595 (piflufolastat f-18) is somewhat higher relative to peers at “ranks #190 of 528 providers nationally (64th percentile; typical, unremarkable volume for this code)”, indicating moderate use of this diagnostic agent compared with national peers rather than market dominance.

Certain services and supportive-care drugs show elevated use relative to peers and stand out as statistical outliers: 99214 (established office visit) is an “extreme outlier, far above typical national volume” at “ranks #8785 of 479517 providers nationally (98th percentile)”, while J2506 (pegfilgrastim) “ranks #18 of 586 providers nationally (97th percentile; notably above typical national volume for this code)” and J9217 (leuprolide acetate) “ranks #124 of 3683 providers nationally (97th percentile; notably above typical national volume for this code)”. These signals point to very high E/M throughput and above-typical provisioning of supportive oncology medications.

Ancillary and laboratory services are consistently high relative to national peers, supporting the interpretation of an active outpatient oncology practice with on-site monitoring: 80053 (CMP) “ranks #1274 of 26416 providers nationally (95th percentile)”, 85025 (CBC) “ranks #1712 of 32833 providers nationally (95th percentile)”, 36415 (venipuncture) “ranks #2412 of 86467 providers nationally (97th percentile)”, and 84153 (PSA) “ranks #468 of 8151 providers nationally (94th percentile)”. The high percentiles for routine labs and blood draws are consistent with frequent treatment cycles and laboratory monitoring.

Imaging utilization shows meaningful but not extreme activity: A9595 is a top-3 revenue driver and “ranks #190 of 528 providers nationally (64th percentile; typical, unremarkable volume for this code)”, while 78815 (PET/CT) “ranks #2462 of 6566 providers nationally (62th percentile; typical, unremarkable volume for this code)”. This pattern suggests the provider routinely orders PET-based diagnostics as part of oncologic care, but imaging volumes are in line with typical national practice rather than indicating unusually high imaging throughput.

The provider has a long-tenure NPI: NPI enumerated (registered) 2006-06-04 (~20 years ago), which indicates an established clinical presence. Combined with the billing mix and high E/M volumes, the tenure supports a picture of an experienced hematology/oncology physician running a mature outpatient infusion and monitoring practice rather than a recently established or sporadic biller.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

77 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	11,200	$40	$481.6K
J9299	Injection, nivolumab, 1 mg	12,200	$20	$292.8K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	300	$480	$143.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,110	$100	$105.4K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1,180	$90	$102.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	80	$1,210	$100.5K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	2,890	$20	$66.5K
J0897	Injection, denosumab, 1 mg	3,360	$20	$60.5K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	420	$130	$55.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	470	$110	$49.9K

Showing 1–10 of 77

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 77 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Vladimir Hugec — 12 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

77 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	12	70	7,200	$40	$323.3K
J9299	3	20	5,240	$20	$159.4K
A9595	4	10	280	$490	$135.8K
J0897	22	90	1,770	$20	$50.8K
J2506	1	20	290	$80	$34.3K
Q5118	3	20	990	$20	$33.7K
Q5119	6	30	1,380	$20	$29.5K
78815	54	180	50	$250	$25.6K
J0881	4	20	10,680	$1	$25.4K
A9552	17	60	30	$370	$17.2K

Showing 1–10 of 77

Related Providers

Other providers that share a Tax Identification Number (TIN) with Vladimir Hugec, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Holland Center	MN	Developmentally Disabled Services Day Training Agency	$0	$16.3M
Minnesota Oncology Hematology, PA	MN	Hematology & Oncology Physician	$0	$8.1M
Robert Delaune	MN	Hematology & Oncology Physician	$1.9M	$0
Yang Liu	MN	Hematology & Oncology Physician	$1.4M	$0
David King	MN	Medical Oncology Physician	$1.3M	$0
Avina Singh	MN	Hematology & Oncology Physician	$971.9K	$0
Ben Zhang	MN	Hematology & Oncology Physician	$914.4K	$0
Uzma Ali	MN	Hematology & Oncology Physician	$868.9K	$0
Samith Thomas Kochuparambil	MN	Hematology & Oncology Physician	$827.8K	$0
Ryan Funk	MN	Radiation Oncology Physician	$716.7K	$0

Nearby Providers

Other providers in the same ZIP code as Vladimir Hugec, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rem Ramsey, Inc.	MN	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$207.6M
Community Dental Care Inc	MN	General Practice Dentistry	$0	$30.7M
Senior Home Living Inc	MN	Personal Care Attendant	$0	$29.4M
Rainbow Home Healthcare Inc	MN	Home Health Agency	$0	$22.2M
Healtheast St. John's Hospital	MN	General Acute Care Hospital	$0	$17.9M
Cochran Recovery Services	MN	Substance Abuse Rehabilitation Facility	$0	$15.4M
Ardent Home Health Care Inc.	MN	Home Health Agency	$0	$12.2M
First Nations, LLC	MN	In Home Supportive Care Agency	$0	$11.3M
Hmong Minnesota Senior Center	MN	Adult Day Care Clinic/Center	$0	$10M
Healtheast Medical Research Institute	MN	Clinic/Center	$0	$7.4M

Vladimir Hugec — Billing Profile & Reimbursement Data

Sign up for Vladimir Hugec — Billing Profile & Reimbursement Data policy alerts

Vladimir Hugec — Billing Profile & Reimbursement Data

Sign up for Vladimir Hugec — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References